Cardiac Failure Review最新文献_第10页

Cardiopulmonary Ultrasonography for Severe Coronavirus Disease 2019 Patients in Prone Position. 重症冠状病毒病2019患者俯卧位心肺超声检查

Cardiac Failure Review Pub Date : 2020-05-14 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.12

Aniket S Rali, Sergio Trevino, Edward Yang, James P Herlihy, Jose Diaz-Gomez

{"title":"Cardiopulmonary Ultrasonography for Severe Coronavirus Disease 2019 Patients in Prone Position.","authors":"Aniket S Rali, Sergio Trevino, Edward Yang, James P Herlihy, Jose Diaz-Gomez","doi":"10.15420/cfr.2020.12","DOIUrl":"https://doi.org/10.15420/cfr.2020.12","url":null,"abstract":"Case Presentation A 50-year old female presented to the emergency department with a 6-day history of fever, progressively worsening cough and shortness of breath. The patient did not report any contact with anyone who had been recently unwell or had been travelling. Upon arrival to the emergency room, the patient was noted to be severely hypoxaemic by pulse oximetry (66%) and in impeding respiratory failure, so she was emergently intubated for mechanical ventilatory support. Immediately post-intubation, arterial blood gas was as follows: pH 7.34, pCO 2 31 mmHg, pO 2 60 mmHg, O 2 saturation 90%, calculated HCO 3 16 mmol/l on FiO 2 of 100% and PaO 2 /FIO 2 ratio of 60. Her ventilatory mode was set at controlled minute ventilation, with a respiratory rate of 24, tidal volume of 300 cc (6 cc/ ideal body weight), positive end-expiratory pressure (PEEP) of 20 cmH 2 O and FiO 2 of 100%. The patient’s chest X-ray at the time of admission showed diffuse bilateral pulmonary opacities consistent with multifocal pneumonia or pulmonary oedema (Figure 1). Polymerase chain reaction (PCR) testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was sent and came back positive after 48 hours.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e12"},"PeriodicalIF":0.0,"publicationDate":"2020-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6e/0f/cfr-06-e12.PMC7265100.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38023337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Artificial Intelligence, Data Sensors and Interconnectivity: Future Opportunities for Heart Failure. 人工智能、数据传感器和互联:心力衰竭的未来机遇。

Cardiac Failure Review Pub Date : 2020-05-12 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2019.14

Patrik Bachtiger, Carla M Plymen, Punam A Pabari, James P Howard, Zachary I Whinnett, Felicia Opoku, Stephen Janering, Aldo A Faisal, Darrel P Francis, Nicholas S Peters

{"title":"Artificial Intelligence, Data Sensors and Interconnectivity: Future Opportunities for Heart Failure.","authors":"Patrik Bachtiger, Carla M Plymen, Punam A Pabari, James P Howard, Zachary I Whinnett, Felicia Opoku, Stephen Janering, Aldo A Faisal, Darrel P Francis, Nicholas S Peters","doi":"10.15420/cfr.2019.14","DOIUrl":"https://doi.org/10.15420/cfr.2019.14","url":null,"abstract":"A higher proportion of patients with heart failure have benefitted from a wide and expanding variety of sensor-enabled implantable devices than any other patient group. These patients can now also take advantage of the ever-increasing availability and affordability of consumer electronics. Wearable, on- and near-body sensor technologies, much like implantable devices, generate massive amounts of data. The connectivity of all these devices has created opportunities for pooling data from multiple sensors - so-called interconnectivity - and for artificial intelligence to provide new diagnostic, triage, risk-stratification and disease management insights for the delivery of better, more personalised and cost-effective healthcare. Artificial intelligence is also bringing important and previously inaccessible insights from our conventional cardiac investigations. The aim of this article is to review the convergence of artificial intelligence, sensor technologies and interconnectivity and the way in which this combination is set to change the care of patients with heart failure.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e11"},"PeriodicalIF":0.0,"publicationDate":"2020-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/62/04/cfr-06-e11.PMC7265101.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38023336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Cardiovascular Clinical Trials in a Pandemic: Immediate Implications of Coronavirus Disease 2019. 大流行中的心血管临床试验:2019冠状病毒病的直接影响

Cardiac Failure Review Pub Date : 2020-05-01 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.07

Ernest Spitzer, Ben Ren, Jasper J Brugts, Joost Daemen, Eugene McFadden, Jan Gp Tijssen, Nicolas M Van Mieghem

引用次数: 5

High-flow Nasal Cannula Oxygenation Revisited in COVID-19. 高流量鼻插管氧合在COVID-19中的应用

Cardiac Failure Review Pub Date : 2020-04-21 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2020.06

Aniket S Rali, Krishidhar R Nunna, Christopher Howard, James P Herlihy, Kalpalatha K Guntupalli

引用次数: 5

Telemonitoring for the Management of Patients with Heart Failure. 心衰患者的远程监护管理。

Cardiac Failure Review Pub Date : 2020-04-21 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2019.20

Ferdinando Iellamo, Barbara Sposato, Maurizio Volterrani

{"title":"Telemonitoring for the Management of Patients with Heart Failure.","authors":"Ferdinando Iellamo, Barbara Sposato, Maurizio Volterrani","doi":"10.15420/cfr.2019.20","DOIUrl":"https://doi.org/10.15420/cfr.2019.20","url":null,"abstract":"Advances in technology now make it possible to manage heart failure (HF) from a remote to a telemonitoring approach using either noninvasive solutions or implantable devices. Nowadays, it is possible to monitor at-home parameters that can be recorded, stored and remotely transmitted to physicians, allowing them to make decisions for therapeutic modification, hospitalization or access to the emergency room. Standalone systems are available that are equipped with self-intelligence and are able to acquire and elaborate data that can inform the remote physician of impending decompensation before it results in additional complications. The development of miniature implantable devices, which could measure haemodynamic variables and transmit them to a monitor outside the body, offers the possibility for the physician to obtain more frequent evaluations of HF patients and the opportunity to take these data into account in management decisions. At present, several telemonitoring devices are available, but the only Food and Drug Administration-approved system is the cardio-microelectromechanical system, which is an implantable pulmonary arterial pressure (PAP) monitoring device that allows a direct monitoring of the PAP via a sensor implanted in the pulmonary artery. This information is then uploaded to a web-based interface from which healthcare providers can track the results and manage patients. At present, the challenge point for telemedicine management of HF is to find the more relevant biological parameter to monitor the clinical status.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"e07"},"PeriodicalIF":0.0,"publicationDate":"2020-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/03/ae/cfr-06-e07.PMC7199126.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37909594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Telemonitoring in Heart Failure Management. 心衰管理中的远程监护。

Cardiac Failure Review Pub Date : 2020-04-21 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2019.12

Ivo Planinc, Davor Milicic, Maja Cikes

引用次数: 14

Long-term Outcome of Pulmonary Vein Isolation Versus Amiodarone Therapy in Patients with Coexistent Persistent AF and Congestive Heart Failure. 肺静脉隔离与胺碘酮治疗并发持续性房颤和充血性心力衰竭患者的长期疗效比较。

Cardiac Failure Review Pub Date : 2020-04-09 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2019.03

Michela Faggioni, Domenico G Della Rocca, Sanghamitra Mohanty, Chintan Trivedi, Ugur Canpolat, Carola Gianni, Amin Al-Ahmad, Rodney Horton, Gerald Joseph Gallinghouse, John David Burkhardt, Andrea Natale

引用次数: 0

The Use of App-based Follow-up of Cardiac Implantable Electronic Devices. 心脏植入式电子装置app随访的应用。

Cardiac Failure Review Pub Date : 2020-04-09 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2019.13

Paul Richard Roberts, Mohamed Hassan ElRefai

引用次数: 10

Pulmonary Hypertension in Heart Failure Patients. 心力衰竭患者的肺动脉高压。

Cardiac Failure Review Pub Date : 2020-04-09 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2019.09

Sriram D Rao, Srinath Adusumalli, Jeremy A Mazurek

引用次数: 12

Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction. 保留射血分数对心力衰竭致瘤性2的抑制作用。

Cardiac Failure Review Pub Date : 2020-03-16 eCollection Date: 2020-03-01 DOI: 10.15420/cfr.2019.10

Veronika Zach, Felix Lucas Bähr, Frank Edelmann

{"title":"Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction.","authors":"Veronika Zach, Felix Lucas Bähr, Frank Edelmann","doi":"10.15420/cfr.2019.10","DOIUrl":"https://doi.org/10.15420/cfr.2019.10","url":null,"abstract":"Heart failure (HF), with steadily increasing incidence rates and mortality in an ageing population, represents a major challenge. Evidence suggests that more than half of all patients with a diagnosis of HF suffer from HF with preserved ejection fraction (HFpEF). Emerging novel biomarkers to improve and potentially guide the treatment of HFpEF are the subject of discussion. One of these biomarkers is suppression of tumourigenicity 2 (ST2), a member of the interleukin (IL)-1 receptor family, binding to IL-33. Its two main isoforms - soluble ST2 (sST2) and transmembrane ST2 (ST2L) - show opposite effects in cardiovascular diseases. While the ST2L/IL-33 interaction is considered as being cardioprotective, sST2 antagonises this beneficial effect by competing for binding to IL-33. Recent studies show that elevated levels of sST2 are associated with increased mortality in HF with reduced ejection fraction. Nevertheless, the significance of sST2 in HFpEF remains uncertain. This article aims to give an overview of the current evidence on sST2 in HFpEF with an emphasis on prognostic value, clinical association and interaction with HF treatment. The authors conclude that sST2 is a promising biomarker in HFpEF. However, further research is needed to fully understand underlying mechanisms and ultimately assess its full value.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"6 ","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2020-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/74/e6/cfr-06-e02.PMC7111301.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37808966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9